Rapid Micro Biosystems prelim FY2022 revenue $17.0-17.2M; Q4 $4.2-4.4M; cash $140M

RAPID MICRO BIOSYSTEMS, INC.

2022-FY EPS reported -$1.43 revenue$17,133,000

FY2022 commercial revenue expected $17.0-17.2M; Q4 revenue $4.2-4.4M, in line with expectations.
Placed 9 new Growth Direct systems and completed validation of 19 systems in FY2022.
Ended 2022 with ~$140M cash and investments, providing runway at least into 2026.
Added new global Top 20 pharma customer in U.S. and large pharma customer in Japan.
Launched RMBNucleus Mold Alarm software; to present at J.P. Morgan Healthcare Conference Jan 12.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

RAPID MICRO BIOSYSTEMS, INC. reported preliminary financial results for fourth quarter and fiscal year ended December 31, 2022.

Period: fourth quarter and fiscal year ended December 31, 2022
Result: preliminary results

Exact text from the filing

On January 11, 2023, Rapid Micro Biosystems, Inc. (the “Company”) issued a press release announcing its preliminary unaudited revenue results for its fourth quarter and fiscal year ended December 31, 2022.

View on SEC.gov

41 earnings releases filed in the last 30 days. Browse all earnings releases →

RAPID MICRO BIOSYSTEMS, INC. filing history →

Source: SEC EDGAR

accession 0001380106-23-000004

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.